Tat-CBD3A6K TFA

Tat-CBD3A6K is a peptide inhibitor derived from Tat-CBD3 that targets the Cav2.2-CRMP2 interaction. It has demonstrated in vivo efficacy in a rat model of antiretroviral-induced neuropathic pain, preserving paw withdrawal thresholds and reducing DRG neuron excitability. In vitro and in vivo studies also show it modulates meningeal blood flow responses, supporting its research use in neuropathic pain mechanisms.